- Home
- ANNX vs GOOD Comparison
ANNX vs GOOD Comparison
Compare ANNX & GOOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- GOOD
- Stock Information
- Founded
- ANNX 2011
- GOOD 2003
- Country
- ANNX United States
- GOOD United States
- Employees
- ANNX N/A
- GOOD N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- GOOD Real Estate Investment Trusts
- Sector
- ANNX Health Care
- GOOD Real Estate
- Exchange
- ANNX Nasdaq
- GOOD Nasdaq
- Market Cap
- ANNX 622.3M
- GOOD 673.3M
- IPO Year
- ANNX 2020
- GOOD N/A
- Fundamental
- Price
- ANNX $7.36
- GOOD $17.06
- Analyst Decision
- ANNX Strong Buy
- GOOD Buy
- Analyst Count
- ANNX 7
- GOOD 2
- Target Price
- ANNX $15.80
- GOOD $15.25
- AVG Volume (30 Days)
- ANNX 1.3M
- GOOD 216.4K
- Earning Date
- ANNX 11-19-2024
- GOOD 11-04-2024
- Dividend Yield
- ANNX N/A
- GOOD 7.04%
- EPS Growth
- ANNX N/A
- GOOD N/A
- EPS
- ANNX N/A
- GOOD 0.21
- Revenue
- ANNX N/A
- GOOD $147,922,000.00
- Revenue This Year
- ANNX N/A
- GOOD N/A
- Revenue Next Year
- ANNX N/A
- GOOD $2.06
- P/E Ratio
- ANNX N/A
- GOOD $81.99
- Revenue Growth
- ANNX N/A
- GOOD N/A
- 52 Week Low
- ANNX $2.05
- GOOD $11.79
- 52 Week High
- ANNX $8.40
- GOOD $17.53
- Technical
- Relative Strength Index (RSI)
- ANNX 55.04
- GOOD 66.97
- Support Level
- ANNX $6.85
- GOOD $15.46
- Resistance Level
- ANNX $7.63
- GOOD $17.53
- Average True Range (ATR)
- ANNX 0.29
- GOOD 0.39
- MACD
- ANNX -0.06
- GOOD 0.08
- Stochastic Oscillator
- ANNX 57.30
- GOOD 77.29
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.